Pradžia › Leukemija › Virginia
Leukemija klinikiniai tyrimai Virginia
7 tyrimai dėl Leukemija ieško dalyvių vietose Virginia.
Miestai Virginia
Oficialus tyrimo tekstas (anglų kalba)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 3, Charlottesville
Renkami dalyviai3 fazė
Amžius nuo 18 iki 71 · Visoms lytims · Atnaujinta 2026-09-23 · NCT07504458Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Virginia School of Medicine, Charlottesville
- Virginia Cancer Specialists, Manassas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Virginia Comprehensive Cancer Center, Charlottesville
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Richmond
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT06137118A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Charlottesville
- Dren Investigational Site, Fairfax
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-17 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Virginia Commonwealth University/Massey Cancer Center, Richmond
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.